z-logo
open-access-imgOpen Access
Efficacy of mupirocin in methicillin-resistant Staphylococcus aureus burn wound infection
Author(s) -
H. Rode,
D. Hanslo,
P. M. De Wet,
A. J. W. Millar,
S. Cywes
Publication year - 1989
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.33.8.1358
Subject(s) - mupirocin , medicine , total body surface area , silver sulfadiazine , staphylococcus aureus , methicillin resistant staphylococcus aureus , antibiotics , chlorhexidine , burn wound , skin infection , body surface area , staphylococcal infections , surgery , microbiology and biotechnology , wound healing , dentistry , biology , bacteria , genetics
Methicillin-resistant Staphylococcus aureus strains (MRSA) have become increasingly prevalent as nosocomial pathogens, especially in burn wounds. MRSA constituted 38% of all S. aureus isolates in our 25-bed burns unit despite the utilization of a combination of 1% silver sulfadiazine and 0.2% chlorhexidine as topical therapy. Mupirocin, a new antibiotic, has proved in vitro and in vivo to be highly effective in the treatment of MRSA infections. A prospective clinical trial with mupirocin ointment in MRSA burn wound infection was untertaken. Forty-five children with 59 discrete burn wounds and from whom MRSA were isolated were treated with 2% mupirocin ointment under occlusive dressings, applied twice daily for 5 days. The average burned area treated was 8% (range, 2 to 20%) of the total body surface area. The burn wounds were assessed clinically and bacteriologically daily. Mupirocin eliminated MRSA in all 59 wounds treated, with the maximum therapeutic response seen within 4 days. In three wounds, gram-negative organisms persisted after 5 days of topical therapy. Treatment was well tolerated by all children. We recommend that mupirocin in its present polyethylene glycol base should be used only on a selective basis, when current prophylactic topical therapy has failed to control MRSA infection in burns of less than 20% of the total body surface area, and that it should be applied only for a limited period of 5 days. The safety and the efficacy of mupirocin in burns exceeding 20% of the total body surface area need to be established.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here